Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PIFELTRO | Merck Sharp & Dohme | N-210806 RX | 2018-08-30 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DELSTRIGO | Merck Sharp & Dohme | N-210807 RX | 2018-08-30 | 1 products, RLD, RS |
Expiration | Code | ||
---|---|---|---|
DORAVIRINE, PIFELTRO, MSD MERCK CO | |||
2025-01-27 | NPP | ||
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO | |||
2025-01-27 | NPP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 5 | 8 | 12 | 6 | 7 | 36 |
Hiv | D006678 | — | O98.7 | 3 | 1 | 1 | 7 | 2 | 14 |
Weight gain | D015430 | HP_0004324 | — | — | — | — | 2 | 1 | 3 |
Drug interactions | D004347 | — | — | 1 | — | — | 1 | — | 2 |
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | 1 | — | 2 |
Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | 1 | — | 2 |
Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 1 | — | 1 |
Contraception | D003267 | — | — | — | — | — | 1 | — | 1 |
Hiv-associated lipodystrophy syndrome | D039682 | EFO_1001348 | — | — | — | — | 1 | — | 1 |
Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv-1 | D015497 | — | — | 1 | 1 | 1 | — | — | 3 |
Hiv-2 | D015498 | — | — | — | — | 1 | — | — | 1 |
Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | 1 | — | — | 1 |
Body weight changes | D001836 | — | — | — | — | 1 | — | — | 1 |
Fasting | D005215 | EFO_0002756 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart disease risk factors | D000082742 | — | — | 1 | — | — | — | — | 1 |
Lipid metabolism disorders | D052439 | — | — | 1 | — | — | — | — | 1 |
Gender dysphoria | D000068116 | — | F64 | 1 | — | — | — | — | 1 |
Latent tuberculosis | D055985 | — | Z22.7 | 1 | — | — | — | — | 1 |
Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
Drug common name | Doravirine |
INN | doravirine |
Description | Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.
|
Classification | Small molecule |
Drug class | antivirals: non-nucleoside reverse transcriptase inhibitors, not benzoxazinone derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O |
PDB | — |
CAS-ID | 1338225-97-0 |
RxCUI | — |
ChEMBL ID | CHEMBL2364608 |
ChEBI ID | — |
PubChem CID | 58460047 |
DrugBank | DB12301 |
UNII ID | 913P6LK81M (ChemIDplus, GSRS) |